Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Sarcomas of the Central Nervous System
NCT03641326Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Feb 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in Gliosarcoma (GS) and central nervous system sarcoma (3 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate. Started Feb 2019; status: terminated.
02
Drugs
sunitinib
03
Conditions
Gliosarcoma (GS)central nervous system sarcoma
Beyond the preview
Go deeper on NCT03641326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03641326.